Cargando…
Cardiac adverse reactions with off-label Covid-19 treatments
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256916/ http://dx.doi.org/10.1007/s40278-020-79028-9 |
Ejemplares similares
-
Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador
Publicado: (2021) -
Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide(®))
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2011) -
Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014) -
Vaccination-associated cardiac adverse events rare
Publicado: (2022) -
“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
por: Gérard, Alexandre, et al.
Publicado: (2020)